Back to today’s briefing

Story perspectives

FDA Approves Mounjaro to Cut Heart Attack, Stroke Risk

8/31/2026

18 1 Full Breakdown

Summary

Story summary

The U.S. FDA approved Eli Lilly’s diabetes drug Mounjaro to lower heart-attack and stroke risk in adults with type 2 diabetes.
A trial of over 13,000 patients showed Mounjaro cut major cardiac events by 8% versus Trulicity.
Deaths from any cause were 16% lower among patients taking Mounjaro in the study.
Lilly’s Mounjaro sales rose 91% to $9.94 billion in Q2, driven by strong demand.

1 of 1

Story summary

The U.S. FDA approved Eli Lilly’s diabetes drug Mounjaro to lower heart-attack and stroke risk in adults with type 2 diabetes.
A trial of over 13,000 patients showed Mounjaro cut major cardiac events by 8% versus Trulicity.
Deaths from any cause were 16% lower among patients taking Mounjaro in the study.
Lilly’s Mounjaro sales rose 91% to $9.94 billion in Q2, driven by strong demand.